{
  "meta": {
    "title": "00205_Mid_Day_Pyqs_Neet_Pg_-_Final_21",
    "url": "https://brainandscalpel.vercel.app/00205-mid-day-pyqs-neet-pg-final-21-ad21699d.html",
    "scrapedAt": "2025-11-29T18:14:10.826Z"
  },
  "questions": [
    {
      "id": 56961,
      "choices": [
        {
          "id": 227233,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue warfarin</span></span></span></p>"
        },
        {
          "id": 227234,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch to LMWH</span></span></span></p>"
        },
        {
          "id": 227235,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate caesarean</span></span></span></p>"
        },
        {
          "id": 227236,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Immediate IOL</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A primigravida presents at 37 weeks. She is a known case of heart disease with a prosthetic valve on warfarin. What is the next best step?&nbsp;</span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2024)</span></span></p>",
      "unique_key": "Q7066339",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948813,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Switch to LMWH</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is a 37-week pregnant woman with a known case of heart disease and a prosthetic valve, currently on warfarin. In pregnant patients with prosthetic heart valves, anticoagulation management is crucial to prevent thromboembolic complications. Warfarin is typically avoided in the late third trimester due to the risk of fetal bleeding and other complications during delivery. It is recommended to switch from warfarin to heparin (usually low molecular weight heparin, LMWH) at around 36 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the patient is still on warfarin at 37 weeks, the immediate action is to switch to LMWH to reduce the risks associated with warfarin during labor and delivery. <strong>Before planning an induction of labor (IOL) or cesarean section, heparin should be stopped 12-24 hours before the planned delivery to minimize the risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Continue warfarin</span></strong><span style=\"font-size:12.0pt\">: Continuing warfarin at this stage is inappropriate because it increases the risk of bleeding for both the mother and the fetus during labor or delivery. Warfarin crosses the placenta and poses significant risks during the peripartum period.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immediate cesarean</span></strong><span style=\"font-size:12.0pt\">: There is no immediate indication for a cesarean section based on her anticoagulation status alone. Cesarean delivery would only be indicated for obstetric reasons. Moreover, performing surgery while the patient is on warfarin increases the risk of severe bleeding complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Immediate IOL (Induction of Labor)</span></strong><span style=\"font-size:12.0pt\">: Immediate induction of labor is not the first step as the patient is still on warfarin, which poses a bleeding risk. Before planning any delivery method, it is essential to switch to heparin and allow a safe window without anticoagulation before proceeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In pregnant women with prosthetic heart valves on warfarin, switch to low molecular weight heparin (LMWH) at 36 weeks to reduce the risk of complications during delivery, and stop heparin 12-24 hours before planned delivery.</span></span></span></p>",
      "correct_choice_id": 227234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83973,
      "choices": [
        {
          "id": 334476,
          "text": "<p><span style=\"font-size:16px;\">Succinyl Choline</span></p>"
        },
        {
          "id": 334477,
          "text": "<p><span style=\"font-size:16px;\">Vecuronium</span></p>"
        },
        {
          "id": 334478,
          "text": "<p><span style=\"font-size:16px;\">Rocuronium</span></p>"
        },
        {
          "id": 334479,
          "text": "<p><span style=\"font-size:16px;\">Cisatracurium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:16px;\">Which of The following muscle relaxants injection causes maximal pain?<strong>&nbsp;</strong>(NEET PG 2016)</span></p>",
      "unique_key": "Q2290581",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948814,
      "difficulty_level": "intermediate",
      "subjects_id": [
        19
      ],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. C) Rocuronium</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Rocuronium is known to cause the <strong>most intense injection pain</strong> among non-depolarizing neuromuscular blockers. The pain is often immediate and described as burning or stinging, largely due to its <strong>low pH&nbsp;</strong>and osmolality, which irritate the vascular endothelium. Pain on injection can occur in <strong>50–80%</strong> of patients when no pretreatment is given. To minimize discomfort, <strong>lidocaine pretreatment</strong> or administration after induction with <strong>propofol</strong> is commonly practiced.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Succinylcholine:</strong> Although succinylcholine may lead to <strong>postoperative myalgia</strong>, it typically <strong>does not cause pain on injection</strong>. Because it is administered rapidly after induction, any injection-related discomfort is rarely noticed.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option B. Vecuronium:</strong> Vecuronium is <strong>virtually painless</strong> on injection. With a near-neutral pH, it is well tolerated and often selected when avoiding injection discomfort is important.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Cisatracurium:</strong> Cisatracurium causes <strong>minimal to no injection pain</strong>. It has a more stable pH and a lower propensity for histamine release compared to atracurium, its parent compound.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Rocuronium causes the most injection pain among neuromuscular blockers, and pretreatment is often needed to reduce discomfort<strong>.</strong></span></p>",
      "correct_choice_id": 334478,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6534,
      "choices": [
        {
          "id": 26105,
          "text": "<p><span style=\"font-size:12.0pt;\">Clozapine</span></p>"
        },
        {
          "id": 26106,
          "text": "<p><span style=\"font-size:12.0pt;\">Donepezil</span></p>"
        },
        {
          "id": 26107,
          "text": "<p><span style=\"font-size:12.0pt;\">Selegiline</span></p>"
        },
        {
          "id": 26108,
          "text": "<p><span style=\"font-size:12.0pt;\">Haloperidol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An elderly man presents with rigidity and tremors. On examination, he has blank facial expressions. Which of the following drugs can be used to manage this condition? (NEET PG 2022)</span></p>",
      "unique_key": "Q7492175",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948815,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Selegiline</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The patient's symptoms of rigidity, tremors, and blank facial expressions are suggestive of Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Selegiline is a monoamine oxidase B (MAO-B) inhibitor that is used in the management of Parkinson's disease. It works by inhibiting the breakdown of dopamine, thereby increasing its availability in the brain and helping to alleviate symptoms like rigidity and tremors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Clozapine</strong>: Clozapine is an atypical antipsychotic primarily used in the treatment of schizophrenia. While it can be used in Parkinson's disease patients who experience psychosis, it is not a first-line treatment for the primary motor symptoms of Parkinson's disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Donepezil</strong>: Donepezil is an acetylcholinesterase inhibitor used in the treatment of Alzheimer’s disease. It enhances cholinergic function by increasing the concentration of acetylcholine in the brain. It is not typically used for treating Parkinson's disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Haloperidol</strong>: Haloperidol is a typical antipsychotic and can actually worsen Parkinson's disease symptoms. It blocks dopamine receptors, which could exacerbate the dopamine deficiency characteristic of Parkinson's disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Selegiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine availability in the brain and is used to manage the motor symptoms of Parkinson's disease, such as rigidity and tremors.</span></p>",
      "correct_choice_id": 26107,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79495,
      "choices": [
        {
          "id": 316715,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmoglein 1</span></p>"
        },
        {
          "id": 316716,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmoglein 3</span></p>"
        },
        {
          "id": 316717,
          "text": "<p><span style=\"font-size:12.0pt;\">Desmoglein 1 and 3</span></p>"
        },
        {
          "id": 316718,
          "text": "<p><span style=\"font-size:12.0pt;\">None</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which antibodies are characterized against Mucocutaneous Pemphigus Vulgaris? (NEET PG 2016)</span></p>",
      "unique_key": "Q6866620",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948816,
      "difficulty_level": "beginner",
      "subjects_id": [
        18
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Desmoglein 1 and 3.</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Mucocutaneous Pemphigus Vulgaris is characterized by antibodies against <strong>both Desmoglein 1 and Desmoglein 3</strong>.&nbsp;</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/9.jpg\" width=\"1010\" height=\"518\"></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">In Pemphigus vulgaris, the target antigens are <strong>\"Desmoglein-3 &gt; 1,\"</strong> which means both are involved but Desmoglein-3 is predominant.&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">While <strong>mucosal-dominant PV</strong> has antibodies primarily against <strong>Desmoglein 3</strong>, mucocutaneous PV (affecting<strong> both skin and mucosa</strong>) requires antibodies to<strong> both Desmoglein 1 and 3.&nbsp;</strong></span></li><li><span style=\"font-size:12.0pt;\">The presence of both antibodies explains the development of skin lesions in addition to oral involvement.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Desmoglein 1:</strong>&nbsp;</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">This is primarily the target antigen in <strong>Pemphigus foliaceus</strong>. When <strong>only anti-Dsg1 antibodies&nbsp;</strong>are present, they cause skin lesions without mucosal involvement.&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">Isolated anti-Dsg1 antibodies cannot explain the mucocutaneous manifestation of PV.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Desmoglein 3:</strong>&nbsp;</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">While <strong>anti-Dsg3</strong> antibodies are <strong>predominant in Pemphigus vulgaris</strong>, having only anti-Dsg3 antibodies typically results in <strong>mucosal-dominant disease.&nbsp;</strong></span></li><li><span style=\"font-size:12.0pt;\">Mucocutaneous PV requires both anti-Dsg1 and anti-Dsg3 antibodies.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. None:</strong>&nbsp;</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\">Incorrect as Pemphigus vulgaris definitely has autoantibodies against desmogleins. The absence of anti-desmoglein antibodies would be inconsistent with the diagnosis of Pemphigus vulgaris.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\"><strong>Mucocutaneous Pemphigus vulgaris</strong> requires antibodies against <strong>both Desmoglein 1 and 3,&nbsp;</strong>with Desmoglein-3 antibodies typically being predominant; this combined antibody profile explains the involvement of both skin and mucous membranes.</span></li></ul>",
      "correct_choice_id": 316717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52119,
      "choices": [
        {
          "id": 207977,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is true, reason is true; reason is the correct explanation for the assertion</span></p>"
        },
        {
          "id": 207978,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is true, reason is true; reason is not the correct explanation for the assertion</span></p>"
        },
        {
          "id": 207979,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is false and reason is also true</span></p>"
        },
        {
          "id": 207980,
          "text": "<p><span style=\"font-size:12.0pt;\">Assertion is true and reason is also false</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\"><strong>Assertion (A):</strong> Myocarditis is the common known complication of faucial diphtheria</span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Reason</strong>&nbsp;<strong>(R)</strong>&nbsp;: It is due to bacteremia by diphtheria&nbsp; &nbsp;&nbsp;</span>(INICET MAY 2024)</p><p>&nbsp;</p><p>&nbsp;</p>",
      "unique_key": "Q4793169",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948818,
      "difficulty_level": "intermediate",
      "subjects_id": [
        6
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Assertion is true and reason is also false</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Assertion:</strong> Myocarditis is indeed a common and serious complication of diphtheria, especially in cases of faucial diphtheria. The diphtheria toxin can cause significant damage to the heart muscle, leading to myocarditis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reason:</strong> The assertion that myocarditis is due to bacteremia by diphtheria is incorrect. Diphtheria does not cause bacteremia. Instead, the complications, including myocarditis, are due to the exotoxin produced by the Corynebacterium diphtheriae. The toxin disseminates through the bloodstream, affecting various organs, including the heart, nerves, and kidneys.</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Diphtheria Toxin:</strong> The pathogenesis of diphtheria involves the production of diphtheria toxin, which is a potent exotoxin. This toxin, rather than the bacteria itself, enters the bloodstream (toxemia) and affects distant organs.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Toxemia vs. Bacteremia:</strong> Diphtheria is characterized by toxemia, not bacteremia. The bacteria remain localized at the site of infection (e.g., the throat), but the toxin spreads systemically.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Myocarditis as a Complication:</strong> The diphtheria toxin affects the heart muscle, leading to myocarditis, which is the most common and severe complication of diphtheria. Other complications include neuritis and damage to the adrenal glands.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Assertion is true, reason is true; reason is the correct explanation for the assertion:</strong> Incorrect because the reason given is not the correct explanation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Assertion is true, reason is true; reason is not the correct explanation for the assertion:</strong> Incorrect because the reason itself is false.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Assertion is false and reason is also true:</strong> Incorrect because the assertion is true, but the reason is false.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Myocarditis is a common and serious complication of diphtheria due to the effects of the diphtheria toxin. It is important to recognize that the complications arise from toxemia, not bacteremia.</span></p>",
      "correct_choice_id": 207980,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55454,
      "choices": [
        {
          "id": 221277,
          "text": "<p><span style=\"font-size:12.0pt;\">100 MMR, 50 U5MR</span></p>"
        },
        {
          "id": 221278,
          "text": "<p><span style=\"font-size:12.0pt;\">100 MMR, 30 U5MR</span></p>"
        },
        {
          "id": 221279,
          "text": "<p><span style=\"font-size:12.0pt;\">70 MMR, 25 U5MR</span></p>"
        },
        {
          "id": 221280,
          "text": "<p><span style=\"font-size:12.0pt;\">100 MMR, 12 U5MR</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">As per United Nations Sustainable Development Goals, Targets for MMR and U5MR to be achieved by 2030 are: (FMGE JULY 2024)</span></p>",
      "unique_key": "Q4094900",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948819,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.&nbsp;C) 70 MMR, 25 U5MR</strong></span></p><p><span style=\"font-size:11pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">The United Nations Sustainable Development Goals (SDGs) were established in 2016 as a global agenda to be achieved by 2030. <strong>Among the 17 goals outlined, Goal 3 is specifically focused on health and well-being.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Under this goal:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Target 3.1&nbsp;</strong>aims to reduce the global maternal mortality ratio (MMR) to less than <strong>70 per 100,000 live births</strong>.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Target 3.2&nbsp;</strong>focuses on reducing the under-5 mortality rate (U5MR) to <strong>25 per 1,000 live births</strong> and neonatal mortality to <strong>12 per 1,000 live births</strong>.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">These targets are part of a broader effort to improve health outcomes and ensure universal health coverage by 2030.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The United Nations Sustainable Development Goals aim to reduce the maternal mortality ratio to below 70 per 100,000 live births and the under-5 mortality rate to 25 per 1,000 live births by 2030.</span></p>",
      "correct_choice_id": 221279,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 57638,
      "choices": [
        {
          "id": 229921,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thalassemia</span></span></p>"
        },
        {
          "id": 229922,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anemia of chronic disease</span></span></p>"
        },
        {
          "id": 229923,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron deficiency anemia</span></span></p>"
        },
        {
          "id": 229924,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sideroblastic anemia</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the likely diagnosis in a patient having a &darr; MCV, &darr; MCH, &darr; transferrin saturation, &darr; serum ferritin, and &uarr; Total iron binding capacity? (NEET PG 2024)</span></span></span></p>",
      "unique_key": "Q6208475",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948820,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Iron deficiency anemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The lab findings indicate a <strong>microcytic hypochromic anemia</strong>, as shown by decreased Mean Corpuscular Volume (MCV) and Mean Corpuscular Hemoglobin (MCH).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The iron profile further confirms iron deficiency anemia: low transferrin saturation, low serum ferritin (indicating depleted iron stores), and increased Total Iron Binding Capacity (TIBC), which reflects the body&rsquo;s attempt to bind more iron due to deficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">These findings are classic for iron deficiency anemia, where the primary pathology is a lack of iron needed for hemoglobin synthesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thalassemia</span></strong><span style=\"font-size:12.0pt\">: Thalassemia also presents as microcytic hypochromic anemia, but typically shows normal or increased serum ferritin and normal TIBC due to intact iron stores. The pattern of iron studies here does not fit thalassemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anemia of chronic disease</span></strong><span style=\"font-size:12.0pt\">: This condition often shows low serum iron, but it is characterized by normal or increased ferritin and decreased TIBC, opposite to the findings in this question.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sideroblastic anemia</span></strong><span style=\"font-size:12.0pt\">: Sideroblastic anemia is characterized by ineffective erythropoiesis and abnormal iron incorporation into hemoglobin, leading to ring sideroblasts in the bone marrow. Serum iron is usually increased, and TIBC is normal or decreased, which does not match the iron deficiency profile described here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron deficiency anemia is identified by microcytic hypochromic anemia with low serum ferritin, low transferrin saturation, and high TIBC, reflecting the body&rsquo;s response to insufficient iron availability for hemoglobin synthesis.</span></span></span></p>",
      "correct_choice_id": 229923,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "InvestigationBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5049,
      "choices": [
        {
          "id": 20170,
          "text": "<p><span style=\"font-size:12.0pt;\">Myophosphorylase</span></p>"
        },
        {
          "id": 20171,
          "text": "<p><span style=\"font-size:12.0pt;\">Glucose-6-phosphatase</span></p>"
        },
        {
          "id": 20172,
          "text": "<p><span style=\"font-size:12.0pt;\">Glycogen synthase&nbsp;</span></p>"
        },
        {
          "id": 20173,
          "text": "<p><span style=\"font-size:12.0pt;\">Hexokinase</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Enzyme defect in McArdle’s Disease?(NEET PG 2022)</span></p>",
      "unique_key": "Q3112551",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948821,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Myophosphorylase</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This is the correct answer. McArdle's Disease results from a deficiency of myophosphorylase, which is an enzyme responsible for breaking down glycogen into glucose within muscle cells. The lack of myophosphorylase impairs the ability of muscle cells to release glucose from glycogen during physical activity, leading to muscle fatigue, pain, and other symptoms typically observed in McArdle's Disease patients.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p><span style=\"font-size:11pt;\"><strong>&nbsp;</strong></span></p><p><span style=\"font-size:12.0pt;\"><strong>Option B</strong>.&nbsp;<strong>Glucose-6-phosphatase:&nbsp;</strong>This enzyme is involved in glucose metabolism in the liver, not in muscle cells. Deficiencies in glucose-6-phosphatase lead to other types of Glycogen Storage Diseases, such as Von Gierke's Disease (GSD Ia).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C</strong>.&nbsp;<strong>Glycogen synthase :&nbsp;</strong>While this enzyme plays a role in glycogen metabolism, it is not the enzyme affected in McArdle's Disease. Instead, it is myophosphorylase that is deficient in this condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D</strong>.&nbsp;<strong>Hexokinase:&nbsp;</strong>Hexokinase is involved in the initial steps of glucose metabolism but is not directly related to glycogen breakdown or McArdle's Disease.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">McArdle's disease&nbsp;is Type V glycogen storage disease that occurs due to deficiency of&nbsp;muscle glycogen phosphorylase (Myophosphorylase) enzyme. In this disease, muscle glycogen cannot be used during exercise, so, on strenuous exercise there are muscles cramps. Also, normal or relatively low levels of lactate will be formed from muscle glycogen after exercise.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Reference</u>: Harper’s 31<sup>st</sup> ed/pg- 167</strong></span></p>",
      "correct_choice_id": 20170,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 80058,
      "choices": [
        {
          "id": 318948,
          "text": "<p><span style=\"font-size:12.0pt;\">&nbsp;Queckenstedt’s Test</span></p>"
        },
        {
          "id": 318949,
          "text": "<p><span style=\"font-size:12.0pt;\">Crowe-Beck Test</span></p>"
        },
        {
          "id": 318950,
          "text": "<p><span style=\"font-size:12.0pt;\">Griesinger’s Sign&nbsp;</span></p>"
        },
        {
          "id": 318951,
          "text": "<p><span style=\"font-size:12.0pt;\">Laugier’s Sign</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not used for diagnosing suspected lateral sinus thrombosis? (NEET PG 2017)</span></p>",
      "unique_key": "Q8365787",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948822,
      "difficulty_level": "intermediate",
      "subjects_id": [
        9
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Laugier’s Sign</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Laugier's sign is not used for diagnosing lateral sinus thrombosis. It is actually a sign associated with fracture of the zygomatic arch, where tenderness is elicited on pressing the fractured fragments. This sign has no relationship to lateral sinus thrombosis or any other otological condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Queckenstedt's Test</strong>: This is correctly associated with lateral sinus thrombosis diagnosis. Also called the Tobey-Ayer test, it involves compression of the jugular vein while monitoring CSF pressure via lumbar puncture. In lateral sinus thrombosis, compression of the affected side's jugular vein causes no change in CSF pressure, while compression of the normal side increases CSF pressure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Crowe-Beck Test</strong>: This is correctly used for diagnosing lateral sinus thrombosis. It is an alternative to Queckenstedt's test that avoids lumbar puncture. It involves observing retinal vein engorgement through fundoscopy during jugular compression. With lateral sinus thrombosis, compression of the affected side causes no retinal vein engorgement, while compression of the normal side does.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Griesinger's Sign</strong>: This is correctly associated with lateral sinus thrombosis. It refers to edema and tenderness over the mastoid emissary vein (posterior to the mastoid process), which occurs due to thrombophlebitis extending from the lateral sinus to the emissary vein.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">While Queckenstedt's test, Crowe-Beck test, and Griesinger's sign are all valid diagnostic indicators for lateral sinus thrombosis, Laugier's sign is unrelated and specifically associated with zygomatic arch fractures.</span></p>",
      "correct_choice_id": 318951,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 83771,
      "choices": [
        {
          "id": 333676,
          "text": "<p><span style=\"font-size:12.0pt;\">Post-pneumonectomy</span></p>"
        },
        {
          "id": 333677,
          "text": "<p><span style=\"font-size:12.0pt;\">Pulmonary laceration</span></p>"
        },
        {
          "id": 333678,
          "text": "<p><span style=\"font-size:12.0pt;\">Pneumomediastinum</span></p>"
        },
        {
          "id": 333679,
          "text": "<p><span style=\"font-size:12.0pt;\">Flail chest</span></p>"
        }
      ],
      "text": "<p>A 50-year-old presents with severe chest pain, respiratory distress, and crepitus after a fall from a roof. The X-ray image is shown. Which of the following is the diagnosis? (NEET PG 2017)</p><p>&nbsp;</p><p><img class=\"image_resized\" style=\"aspect-ratio:764/680;width:77.08%;\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/Picture3_ehK83ZH.png\" width=\"764\" height=\"680\"></p>",
      "unique_key": "Q9617344",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948823,
      "difficulty_level": "intermediate",
      "subjects_id": [
        17
      ],
      "solution": "<p><strong>Correct Answer: C. Pneumomediastinum</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong></p><p>&nbsp;</p><p>The X-ray demonstrates air in the mediastinum (pneumomediastinum), visible as lucent streaks outlining mediastinal structures. This finding represents free air that has dissected through fascial planes into the mediastinum. Pneumomediastinum can result from trauma and typically presents with chest pain, respiratory distress, and subcutaneous emphysema (crepitus). The pattern shown matches classic pneumomediastinum signs.</p><p>&nbsp;</p><p><strong>Option C. Pneumomediastinum (CORRECT)</strong></p><ul><li>The image shows characteristic linear lucencies tracking along mediastinal structures</li><li>Air outlines the heart border, trachea, and great vessels</li><li>Associated with subcutaneous emphysema as evidenced by the patient's crepitus</li><li>Common after trauma due to alveolar rupture with air dissecting back along bronchovascular bundles</li></ul><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><p><strong>Option A. Post-pneumonectomy (INCORRECT)</strong></p><ul><li>Post-pneumonectomy shows complete opacification of one hemithorax</li><li>Would demonstrate surgical clips in the region of the hilum</li><li>Would show a shift of the heart and trachea toward the side of the pneumonectomy</li><li>Would have surgical absence of the 5th or 6th rib which is not seen here</li></ul><p>&nbsp;</p><p><strong>Option B. Pulmonary laceration (INCORRECT)</strong></p><ul><li>Pulmonary laceration would appear as a focal area of consolidation in the lung parenchyma</li><li>Would not produce the linear lucent streaks in the mediastinum seen in this image</li><li>Represents a tear in the lung tissue following trauma, but doesn't cause mediastinal air</li><li>Would typically show focal hematoma or contusion patterns within lung fields</li></ul><p>&nbsp;</p><p><strong>Option D. Flail chest (INCORRECT)</strong></p><ul><li>Flail chest requires multiple adjacent rib fractures in at least two places</li><li>While possible after a fall, the image does not show the multiple rib fractures defining this condition</li><li>Would demonstrate paradoxical motion of the chest wall during respiration clinically</li><li>Associated with underlying pulmonary contusion but not specifically with pneumomediastinum</li></ul><p>&nbsp;</p><p><strong>Educational Objective:</strong></p><p>&nbsp;</p><p>Pneumomediastinum appears radiographically as linear lucencies outlining mediastinal structures and can occur after trauma through alveolar rupture with air dissecting along fascial planes, presenting with chest pain, respiratory distress, and subcutaneous emphysema.</p>",
      "correct_choice_id": 333678,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 82625,
      "choices": [
        {
          "id": 329124,
          "text": "<p>GLP-1 (glucagon-like peptide-1)&nbsp;</p>"
        },
        {
          "id": 329125,
          "text": "<p>Leptin&nbsp;</p>"
        },
        {
          "id": 329126,
          "text": "<p>Ghrelin&nbsp;</p>"
        },
        {
          "id": 329127,
          "text": "<p>Insulin &nbsp;</p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following hormones reduces food intake via dual pathways by stimulating melanocyte stimulating hormone and inhibiting AgRP? (NEET PG 2015)</span></p>",
      "unique_key": "Q6738531",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948824,
      "difficulty_level": "intermediate",
      "subjects_id": [
        2
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Correct Answer: B. Leptin&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Leptin is produced by adipose tissue and signals the status of fat stores in the body. As adipocytes increase in size, they release greater quantities of leptin which decreases food intake by increasing the expression of anorexigenic factors in the hypothalamus such as pro-opiomelanocortin (POMC). POMC is the precursor to melanocyte stimulating hormone. Leptin crosses the blood-brain barrier and activates central factors in the hypothalamus that decrease food intake through multiple pathways, including stimulating POMC/melanocyte stimulating hormone while inhibiting orexigenic factors like AgRP.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Option A. GLP-1</strong>: While GLP-1 is a hormone released coincident with meals that plays roles in digestion and absorption, it doesn't have the specific dual effect on melanocyte stimulating hormone and AgRP described in the question.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Option C. Ghrelin</strong>: Contrary to the question, ghrelin is a predominantly fast-acting orexin that stimulates food intake. It increases synthesis/release of central orexins, including neuropeptide Y and cannabinoids, and suppresses the ability of leptin to stimulate anorexigenic factors.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Option D. Insulin</strong>: Insulin doesn't have the specific documented effect on melanocyte stimulating hormone and AgRP pathways related to food intake as described in the question.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Leptin functions as a critical anorexigenic hormone (decreases appetite) by acting on hypothalamic centers through multiple pathways, serving as a key signal from adipose tissue to the brain about the body's energy stores.</span></p>",
      "correct_choice_id": 329125,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 31812,
      "choices": [
        {
          "id": 127118,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Skin rash </span></span></p>"
        },
        {
          "id": 127119,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hepatitis with raised GGT</span></span></p>"
        },
        {
          "id": 127120,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia </span></span></p>"
        },
        {
          "id": 127121,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Blood dyscrasias</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">When comparing oxcarbazepine and carbamazepine, which of the following adverse effects is more commonly associated with oxcarbazepine?</span></span></p>",
      "unique_key": "Q6928742",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948825,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C) Hyponatremia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia, or low sodium levels in the blood, is a known side effect of oxcarbazepine and is more commonly seen with this drug compared to carbamazepine. Oxcarbazepine can cause an inappropriate secretion of antidiuretic hormone (SIADH), leading to water retention and a subsequent dilution of sodium in the body. While both oxcarbazepine and carbamazepine can cause hyponatremia, the incidence is higher with oxcarbazepine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Skin rash:</strong> Skin rashes can occur with both oxcarbazepine and carbamazepine. However, the incidence of skin rash is not significantly higher with oxcarbazepine compared to carbamazepine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Hepatitis with raised GGT:</strong> Hepatitis and elevated GGT levels can occur with carbamazepine, but they are not particularly more common with oxcarbazepine. Both drugs can affect liver enzyme levels, but this is not a distinguishing factor between the two in terms of commonality.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Blood dyscrasias:</strong> Blood dyscrasias, including agranulocytosis and aplastic anemia, are serious but rare side effects of both oxcarbazepine and carbamazepine. There is no significant difference in the incidence of these effects between the two drugs.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Educational Objective:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hyponatremia is more commonly associated with oxcarbazepine compared to carbamazepine, often due to the inappropriate secretion of antidiuretic hormone (SIADH) leading to water retention and dilution of sodium.</span></span></p>",
      "correct_choice_id": 127120,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55500,
      "choices": [
        {
          "id": 221457,
          "text": "<p><span style=\"font-size:12.0pt;\">Reassurance</span></p>"
        },
        {
          "id": 221458,
          "text": "<p><span style=\"font-size:12.0pt;\">Remove IUCD</span></p>"
        },
        {
          "id": 221459,
          "text": "<p><span style=\"font-size:12.0pt;\">Antibiotics and IV fluids</span></p>"
        },
        {
          "id": 221460,
          "text": "<p><span style=\"font-size:12.0pt;\">Iron supplement and observation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A woman who got IUCD inserted at a PHC, now presents with bleeding. What should be done by the MO? (FMGE JULY 2024)</span></p>",
      "unique_key": "Q9187679",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948826,
      "difficulty_level": "difficult",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Iron supplement and observation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bleeding after IUCD (Intrauterine Contraceptive Device) insertion is a common and typically normal physiological response. It is generally expected to subside within the first two menstrual cycles. While reassurance is important, simply reassuring the patient may not be sufficient, as persistent bleeding can lead to anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The best approach is to supplement with iron (e.g., ferrous sulfate 200 mg TDS for 8 weeks) to prevent anemia while observing the patient. If the bleeding does not subside despite supplementation, the IUCD may need to be removed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Reassurance</strong>: While reassurance is important, it alone may not be enough if the bleeding persists and leads to anemia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Remove IUCD</strong>: Immediate removal of the IUCD is not the first line of management unless the bleeding persists despite supplementation and observation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Antibiotics and IV fluids</strong>: These are not indicated unless there is an infection or severe bleeding, which is not mentioned in this scenario.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Iron supplementation and observation</strong> are crucial in managing post-IUCD insertion bleeding to prevent anemia. If bleeding persists, further action, such as removing the IUCD, may be necessary.</span></p>",
      "correct_choice_id": 221460,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55884,
      "choices": [
        {
          "id": 222969,
          "text": "<p><span style=\"font-size:12.0pt;\">T9</span></p>"
        },
        {
          "id": 222970,
          "text": "<p><span style=\"font-size:12.0pt;\">T10</span></p>"
        },
        {
          "id": 222971,
          "text": "<p><span style=\"font-size:12.0pt;\">T11</span></p>"
        },
        {
          "id": 222972,
          "text": "<p><span style=\"font-size:12.0pt;\">T12</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the vertebral level of section in given image? (INICET MAY 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/03/screenshot-2024-09-03-171920.jpeg\" alt=\"\" width=\"300\" height=\"221\"></span></p>",
      "unique_key": "Q8268658",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948827,
      "difficulty_level": "difficult",
      "subjects_id": [
        3
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) T9</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The provided image shows a cross-sectional anatomy where key structures such as the liver, stomach, heart, and lungs are visible. At the T9 vertebral level, the liver and stomach are seen prominently, with the heart also visible, indicating that the section is at the level where these thoracic and upper abdominal structures overlap. The presence of the lungs further supports that this is a thoracic level.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/03/screenshot-2024-09-03-171944.jpeg\" alt=\"\" width=\"500\" height=\"300\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/03/screenshot-2024-09-03-171956.jpeg\" alt=\"\" width=\"700\" height=\"348\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Cross sectional anatomy of ABDOMEN:</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/03/screenshot-2024-09-03-171932.jpeg\" alt=\"\" width=\"700\" height=\"721\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. T10:</strong> While the T10 level also shows some of the same structures, the visibility and position of the liver, stomach, heart, and lungs in this image are more indicative of T9.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. T11:</strong> At the T11 level, the kidneys start to become visible, and the heart is usually not as prominent as it is at the T9 level.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. T12:</strong> The T12 level typically shows the kidneys more clearly and does not include as much of the heart and upper liver as seen in the provided image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The T9 vertebral level in cross-sectional anatomy images often shows the liver, stomach, heart, and lungs, making it a key point for identifying these structures.</span></p>",
      "correct_choice_id": 222969,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13777,
      "choices": [
        {
          "id": 55069,
          "text": "<p><span style=\"font-size:12.0pt;\">Extensor digitorum</span></p>"
        },
        {
          "id": 55070,
          "text": "<p><span style=\"font-size:12.0pt;\">Interossei and lumbricals</span></p>"
        },
        {
          "id": 55071,
          "text": "<p><span style=\"font-size:12.0pt;\">Abductor pollicis</span></p>"
        },
        {
          "id": 55072,
          "text": "<p><span style=\"font-size:12.0pt;\">Abductor pollicis brevis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presented with the extension of MCP joint and flexion of IP joints. Which muscle is most likely affected here ? (NEET PG 2020)</span></p>",
      "unique_key": "Q8398859",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948828,
      "difficulty_level": "beginner",
      "subjects_id": [
        3
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Interossei and lumbricals</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Damage to the ulnar nerve can lead to weakness or atrophy of the lumbrical and interossei muscles in the hand.</span></li><li><span style=\"font-size:12.0pt;\">These muscles play a crucial role in flexing the metacarpophalangeal (MCP) joints and extending the interphalangeal (IP) joints through their attachment to the dorsal digital expansions.</span></li><li><span style=\"font-size:12.0pt;\">As a result of the nerve injury, the MCP joints may become extended, while the IP joints may become flexed.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Note: The ulnar nerve innervates all the intrinsic muscles of the hand, except for</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">First and second lumbrical</span></li><li><span style=\"font-size:12.0pt;\">Abductor pollicis brevis</span></li><li><span style=\"font-size:12.0pt;\">Opponens pollicis</span></li><li><span style=\"font-size:12.0pt;\">Part of flexor pollicis brevis</span></li></ul><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/07/screenshot-2023-11-07-172844.jpg\" alt=\"\" width=\"1000\" height=\"471\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Extensor digitorum: </strong>This muscle originates from the lateral epicondyle of the humerus and inserts into the dorsal digital expansions of the medial four fingers.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">It acts primarily to extend the metacarpophalangeal (MCP) and interphalangeal (IP) joints of the fingers.</span></li><li><span style=\"font-size:12.0pt;\">If the extensor digitorum were affected, you would expect difficulty in extending the MCP and IP joints.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C.</strong> <strong>Abductor pollicis</strong>:&nbsp;</span></p><ul><li><span style=\"font-size:12.0pt;\">It refers to two muscles, the abductor pollicis longus (located in the forearm) and abductor pollicis brevis (intrinsic hand muscle) whose primary function is to abduct the thumb. Dysfunction would primarily impact thumb movements and would not lead to the clinical picture described.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D.</strong> <strong>Abductor pollicis brevis</strong>:&nbsp;</span></p><ul><li><span style=\"font-size:12.0pt;\">It is one of the thenar muscles of the hand and plays a key role in thumb movement, especially in its abduction. Like the abductor pollicis longus, an issue with this muscle would impact thumb movements.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Interossei and lumbricals</strong> are the intrinsic muscles of the hand.</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The lumbricals arise from the tendons of the flexor digitorum profundus. They act to flex the MCP joints and extend both the proximal and distal IP joints.</span></li><li><span style=\"font-size:12.0pt;\">The interossei (both dorsal and palmar) act to abduct (DAB - Dorsal Abduct) and adduct (PAD - Palmar Adduct) the fingers at the MCP joints and assist the lumbricals in flexing the MCP joints and extending the IP joints.</span></li><li><span style=\"font-size:12.0pt;\">If these muscles are affected, as indicated in the clinical picture, there would be an extension of the MCP joints and flexion of the IP joints (due to unopposed action of extrinsic flexors and extensors).</span></li></ul>",
      "correct_choice_id": 55070,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5975,
      "choices": [
        {
          "id": 23870,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery - Internal iliac artery</span></p>"
        },
        {
          "id": 23871,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery- External iliac artery</span></p>"
        },
        {
          "id": 23872,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery - Vaginal artery</span></p>"
        },
        {
          "id": 23873,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - pudendal artery - Vaginal artery</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient developed atonic postpartum hemorrhage after a normal vaginal delivery. She was shifted to the OT and the obstetrician planned ligation of vessels to arrest the bleeding. What is the order of ligation of the blood vessels supplying the uterus?&nbsp;</span>(NEET PG 2021)</p>",
      "unique_key": "Q9738561",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948829,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Uterine artery – Ovarian artery – Internal iliac artery</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Stepwise devascularization in the management of atonic postpartum hemorrhage (PPH) involves:</span><ol><li><span style=\"font-size:12pt;\"><strong>Ligation of the uterine arteries:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">The ascending branch of the uterine artery is ligated at the lateral border between the upper and lower uterine segments.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Ligation of the ovarian and uterine artery anastomoses:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">Done just below the ovarian ligament.</span></li><li><span style=\"font-size:12pt;\">Sometimes, temporary occlusion of the ovarian vessels may be achieved using rubber sleeved clamps.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Ligation of the anterior division of the internal iliac artery:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">This step reduces blood flow by decreasing the pulse pressure by 85%.</span></li><li><span style=\"font-size:12pt;\">Ligation can be unilateral or bilateral.</span></li></ul></li></ol></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Uterine artery - Ovarian artery - External iliac artery: </strong>The external iliac artery is not typically involved in the stepwise devascularization for managing atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Uterine artery - Ovarian artery - Vaginal artery: </strong>Ligation of the vaginal artery is not part of the typical sequence in managing atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Uterine artery - pudendal artery - Vaginal artery: </strong>The pudendal artery and vaginal artery are not typically targeted in the stepwise devascularization for atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The stepwise devascularization approach for managing atonic postpartum hemorrhage includes ligation of the uterine arteries, ovarian arteries, and anterior division of the internal iliac arteries in that specific order.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 2023, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23870,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5215,
      "choices": [
        {
          "id": 20832,
          "text": "<p><span style=\"font-size:12.0pt;\">Battle sign</span></p>"
        },
        {
          "id": 20833,
          "text": "<p><span style=\"font-size:12.0pt;\">Bezold abscess</span></p>"
        },
        {
          "id": 20834,
          "text": "<p><span style=\"font-size:12.0pt;\">Mastoiditis</span></p>"
        },
        {
          "id": 20835,
          "text": "<p><span style=\"font-size:12.0pt;\">Griesinger sign</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A person who met with an accident, and suffered from a skull fracture presents with the following finding. Identify this clinical finding. (NEET PG 2020)</span></p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/01/2_lYJPYiL.jpg\" alt=\"\" width=\"300\" height=\"298\"></span></p>",
      "unique_key": "Q9014837",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948830,
      "difficulty_level": "beginner",
      "subjects_id": [
        9
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Battle sign</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image shows Battle's sign.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">It is retroarticular or mastoid ecchymosis that typically results from fracture of middle cranial fossa following head trauma. Battle sign is prominent when there is a fracture of the petrous temporal bone.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B:</strong> Bezold abscess is a complication of acute otomastoiditis where the infection extends into the infratemporal fossa.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong> Mastoiditis presents as retro-auricular redness, swelling which is painful.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D:</strong> The Griesinger sign refers to edema of the postauricular soft tissues overlying the mastoid process as a result of thrombosis of the mastoid emissary vein. It is a complication of acute otomastoiditis</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Battle's sign is a significant diagnostic clue in trauma patients, signaling a possible basilar skull fracture. Recognition of this sign should prompt further diagnostic imaging and careful neurologic assessment to manage potential complications associated with such fractures.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref - Dhingra 7<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 20832,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20841,
      "choices": [
        {
          "id": 83328,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Panic Disorder</span></p>"
        },
        {
          "id": 83329,
          "text": "<p><span style=\"font-size:12.0pt;\">Generalized Anxiety Disorder</span></p>"
        },
        {
          "id": 83330,
          "text": "<p><span style=\"font-size:12.0pt;\">Depression</span></p>"
        },
        {
          "id": 83331,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Social Phobia</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical student presented with complaints of repeated episodes lasting approximately 30 minutes, characterized by breathlessness, palpitations, sweating, hyperventilation, and a fear of an impending heart attack. The patient has experienced these episodes 5-6 times per month over the last 6 months, and investigations did not reveal any obvious abnormalities. What is the likely diagnosis?&nbsp;(NEET PG 2023)</span></p>",
      "unique_key": "Q3090035",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948831,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Panic Disorder</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The clinical presentation of a medical student with repeated episodes of breathlessness, palpitations, sweating, hyperventilation, and fear of an impending heart attack, each lasting approximately 30 minutes and occurring 5-6 times per month over the last 6 months, with no abnormalities found in investigations, is highly suggestive of <strong>Panic Disorder</strong>. Panic Disorder is characterized by recurrent, unexpected panic attacks, which are abrupt surges of intense fear or discomfort reaching a peak within minutes. The symptoms described, including palpitations, sweating, and hyperventilation, are common during panic attacks.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;B. Generalized Anxiety Disorder (GAD):&nbsp;</strong>GAD is characterized by persistent and excessive worry about various things, but it does not typically involve the acute, intense episodes of fear or the physical symptoms of a panic attack.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;C. Depression:&nbsp;</strong>While depression can have anxiety symptoms and panic attacks, the primary feature is a persistent low mood and loss of interest or pleasure in activities, which is not mentioned in this scenario.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option&nbsp;D. Social Phobia: </strong>Also known as social anxiety disorder, this involves a significant fear of social or performance situations. The symptoms described do not specifically relate to social or performance situations, making this diagnosis less likely.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Panic disorder is characterized by recurrent and unexpected panic attacks with anticipatory anxiety. Patients may start ‘avoiding’ situations that they link with the panic attack. Treatment includes a combination of pharmacotherapy [benzodiazepines for short term and SSRIs for long term] and psychotherapy [CBT, relaxation techniques] is preferred.</span></p><p><span style=\"font-size:11pt;\">&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Reference: Kaplan &amp; Sadock’s Synopsis of Psychiatry, 12th edition, Page No 402.</strong></span></p>",
      "correct_choice_id": 83328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6511,
      "choices": [
        {
          "id": 26013,
          "text": "<p><span style=\"font-size:12.0pt;\">Teriparatide can be given along with bisphosphonates.</span></p>"
        },
        {
          "id": 26014,
          "text": "<p><span style=\"font-size:12.0pt;\">Bisphosphonates are not given for more than a year</span></p>"
        },
        {
          "id": 26015,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium requirement is 1200 mg per day</span></p>"
        },
        {
          "id": 26016,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral vitamin D3 is given along with oral calcium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old postmenopausal female patient with a history of Colle's fracture comes to the outpatient department complaining of lower back pain. After undergoing a bone density test, her T score is found to be -2.5. Which of the following statements about the management of her condition is incorrect? (NEET PG 2021)</span></p>",
      "unique_key": "Q6183526",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948832,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Bisphosphonates are not given for more than a year</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This question deals with osteoporotic post-menopausal female, who has a history of fracture as well.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bisphosphonates which act by inhibiting the bone resorption by the osteoclasts form the first line of treatment in this patient. Bisphosphonates are DOC for Osteoporosis (Steroid induced, post-menopausal and due to any reason). These are indicated for 5 years and then a drug holiday of 2-3 years is given to avoid adverse effects (increased risk of bone fractures and osteonecrosis of mandible). These can be repeated for another 5 years after drug holiday.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Teriparatide can be given along with bisphosphonates: </strong>Teriparatide is a parathyroid hormone analog that stimulates bone formation by increasing osteoblast activity. It is particularly useful in patients with severe osteoporosis and a history of fractures. It can be started before bisphosphonates in certain cases.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Calcium requirement is 1200 mg per day: </strong>The recommended daily intake of calcium for postmenopausal women is around 1200 mg. This helps maintain bone density and prevent further bone loss.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Oral vitamin D3 is given along with oral calcium: </strong>Supplementation with oral vitamin D3 (cholecalciferol) along with calcium is essential to ensure proper calcium absorption and to maintain bone health. The recommended dose of vitamin D3 is typically around 800 IU per day.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Bisphosphonates are recommended for up to 5 years, not just one year, in the treatment of osteoporosis in postmenopausal women.</span></p>",
      "correct_choice_id": 26014,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9969,
      "choices": [
        {
          "id": 39842,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrocephalus</span></p>"
        },
        {
          "id": 39843,
          "text": "<p><span style=\"font-size:12.0pt;\">Chorioretinitis</span></p>"
        },
        {
          "id": 39844,
          "text": "<p><span style=\"font-size:12.0pt;\">Hepatosplenomegaly</span></p>"
        },
        {
          "id": 39845,
          "text": "<p><span style=\"font-size:12.0pt;\">Thrombocytopenia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The most common manifestation of congenital toxoplasmosis is: (NEET PG 2019)</span></p>",
      "unique_key": "Q1279973",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948833,
      "difficulty_level": "beginner",
      "subjects_id": [
        13
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Chorioretinitis</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">The most common manifestation of congenital toxoplasmosis is chorioretinitis.</span></li><li><span style=\"font-size:12.0pt;\">Congenital toxoplasmosis is an infection caused by the parasite Toxoplasma gondii that occurs when a pregnant woman becomes infected and passes the infection on to her developing fetus. The severity of the infection can vary depending on the timing of the infection during pregnancy and the degree of immune response mounted by the fetus.</span></li><li><span style=\"font-size:12.0pt;\">It is acquired perorally from ingesting food that contains oocysts; transplacentally, during vaginal delivery; or rarely, parenterally.</span></li><li><span style=\"font-size:12.0pt;\">Chorioretinitis is the most common manifestation of congenital toxoplasmosis, occurring in up to 80% of affected infants. It is a type of eye inflammation that affects the retina and can lead to vision impairment or blindness if left untreated.</span></li><li><span style=\"font-size:12.0pt;\">Other common manifestations of congenital toxoplasmosis include hydrocephalus (accumulation of fluid in the brain), hepatosplenomegaly (enlargement of the liver and spleen), and thrombocytopenia (low platelet count), but these are less common than chorioretinitis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:10.5pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/12/picture13_yKaR1W9.jpg\" alt=\"\" width=\"600\" height=\"433\"></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/28/picture135.jpg\" alt=\"\" width=\"1000\" height=\"670\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Hydrocephalus:&nbsp;</strong>Accumulation of fluid in the brain can occur in congenital toxoplasmosis but is less common than chorioretinitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Hepatosplenomegaly:&nbsp;</strong>Enlargement of the liver and spleen is another possible manifestation but not as common as chorioretinitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Thrombocytopenia:&nbsp;</strong>Low platelet count can occur but is less common compared to chorioretinitis.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Chorioretinitis is the most common manifestation of congenital toxoplasmosis, affecting up to 80% of infected infants and potentially leading to vision impairment or blindness.</span></p>",
      "correct_choice_id": 39843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47986,
      "choices": [
        {
          "id": 191539,
          "text": "<p>Apical nodes</p>"
        },
        {
          "id": 191540,
          "text": "<p>Anterior (pectoral) nodes</p>"
        },
        {
          "id": 191541,
          "text": "<p>Parasternal (internal thoracic) nodes</p>"
        },
        {
          "id": 191542,
          "text": "<p>Supraclavicular nodes</p>"
        }
      ],
      "text": "<p>Lymph from a cancerous breast primarily drains into which of the following nodes? (NEET PG 2017)</p>",
      "unique_key": "Q3337064",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948834,
      "difficulty_level": "intermediate",
      "subjects_id": [
        3
      ],
      "solution": "<p><strong>Correct Answer. B. Anterior (pectoral) nodes</strong></p><p>&nbsp;</p><p><strong>Explanation:</strong>&nbsp;</p><p>&nbsp;</p><p>The lymphatic drainage of the breast primarily flows into the anterior (pectoral) group of axillary lymph nodes. These nodes are positioned along the lateral thoracic vessels at the lower border of the pectoralis minor muscle. Approximately 75% of the lymph from the breast tissue drains into the axillary nodes, with the anterior group receiving the major portion. This makes the anterior (pectoral) nodes the first-line lymph nodes to receive drainage from cancerous breast tissue, particularly from the upper lateral quadrant where breast cancer most commonly occurs.</p><p>&nbsp;</p><p><strong>Other Options:</strong></p><p>&nbsp;</p><ul><li><strong>Option&nbsp;A. Apical nodes</strong>: Located at the apex of the axilla, these nodes receive lymph secondarily after it has passed through other axillary node groups. They're not the primary recipients of breast lymph drainage.</li><li><strong>Option&nbsp;C. Parasternal (internal thoracic) nodes</strong>: These nodes receive about 20% of breast lymphatic drainage, primarily from the medial quadrants of the breast, but are not the main drainage pathway.</li><li><strong>Option&nbsp;D. Supraclavicular nodes</strong>: These become involved primarily in advanced cases of breast cancer. They receive lymph only after it has passed through multiple other node groups.</li></ul><p>&nbsp;</p><p><strong>Educational Objective:</strong>&nbsp;</p><p>&nbsp;</p><p>Anterior (pectoral) lymph nodes are the primary recipients of lymphatic drainage from the breast, making them crucial for early detection and staging of breast malignancy.</p>",
      "correct_choice_id": 191540,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 44018,
      "choices": [
        {
          "id": 175731,
          "text": "<p><span style=\"font-size:12pt;\">Arrythmia</span></p>"
        },
        {
          "id": 175732,
          "text": "<p><span style=\"font-size:12pt;\">Confusion</span></p>"
        },
        {
          "id": 175733,
          "text": "<p><span style=\"font-size:12pt;\">Hypothermia</span></p>"
        },
        {
          "id": 175734,
          "text": "<p><span style=\"font-size:12pt;\">Pupillary dilatation</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient was started on Amitryptiline and he was found to be unconscious. Which of the following doesn’t suggest TCA toxicity ?</span>(INICET NOV 2023)</p>",
      "unique_key": "Q2906224",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948835,
      "difficulty_level": "beginner",
      "subjects_id": [
        16
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Hypothermia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">TCA toxicity typically presents with hyperthermia due to anticholinergic effects, not hypothermia.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/15/screenshot-2024-05-15-165526.JPG\" alt=\"\" width=\"1000\" height=\"445\"></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Arrhythmias: </strong>Arrhythmias are a hallmark of TCA toxicity, reflecting its impact on cardiac conductivity.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Confusion:&nbsp;</strong>Confusion or altered sensorium is common due to the central nervous system effects of TCAs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong> <strong>Pupillary dilatation:</strong> Pupillary dilatation results from the anticholinergic properties of TCAs.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective</strong>:&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In cases of TCA toxicity, we see symptoms like arrhythmias, confusion, and pupillary dilatation due to its anticholinergic and cardiotoxic properties. Hypothermia is not typically associated with TCA overdose.</span></p>",
      "correct_choice_id": 175733,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6514,
      "choices": [
        {
          "id": 26025,
          "text": "<p><span style=\"font-size:12.0pt;\">Potassium chloride</span></p>"
        },
        {
          "id": 26026,
          "text": "<p><span style=\"font-size:12.0pt;\">Clarithromycin</span></p>"
        },
        {
          "id": 26027,
          "text": "<p><span style=\"font-size:12.0pt;\">Atenolol</span></p>"
        },
        {
          "id": 26028,
          "text": "<p><span style=\"font-size:12.0pt;\">Triamterene</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old male patient was diagnosed with atrial fibrillation with a controlled ventricular rate. The medication charts reveal that he was taking digoxin, potassium chloride, clarithromycin, atenolol, and triamterene. Suspecting the symptoms to be due to digoxin overdose, plasma levels of digoxin were ordered. It was found that his blood levels of digoxin have increased significantly. Which of his medications is most likely responsible for this increase in digoxin levels? (NEET PG 2021)</span></p>",
      "unique_key": "Q1153669",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948836,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Clarithromycin.</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Clarithromycin is known to inhibit the cytochrome P450 system, which is involved in the metabolism of many drugs, including digoxin. By inhibiting the metabolism of digoxin, clarithromycin can lead to elevated levels of digoxin in the blood, increasing the risk for digoxin toxicity.</span></li><li><span style=\"font-size:12.0pt;\">Clarithromycin also acts as an inhibitor of the P-glycoprotein and can precipitate Digoxin toxicity. P glycoproteins are drug efflux pumps in the intestine that lead to a decrease in the bioavailability of drugs. Digoxin is one of the drugs that utilizes this mechanism for its metabolism. Therefore, the drugs which inhibit the Pgp can lead to the increased plasma concentration of Digoxin and lead to its toxicity.</span></li><li><span style=\"font-size:12.0pt;\">Other drugs that inhibit the Pgp include&nbsp;</span><ul><li><span style=\"font-size:12.0pt;\">Amiodarone</span></li><li><span style=\"font-size:12.0pt;\">Verapamil</span></li><li><span style=\"font-size:12.0pt;\">Diltiazem</span></li><li><span style=\"font-size:12.0pt;\">Itraconazole</span></li><li><span style=\"font-size:12.0pt;\">Propafenone</span></li><li><span style=\"font-size:12.0pt;\">Flecainide&nbsp;</span></li><li><span style=\"font-size:12.0pt;\">Quinidine.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Potassium chloride:</strong> This medication primarily affects potassium levels and has no significant interaction with digoxin metabolism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Atenolol</strong>: Atenolol, a beta-blocker, is not known to significantly interact with digoxin metabolism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Triamterene</strong>: This diuretic medication primarily affects sodium and potassium levels and is not known to have a significant impact on digoxin metabolism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Clarithromycin can significantly increase plasma levels of digoxin by inhibiting its metabolism through the cytochrome P450 system and by inhibiting P-glycoprotein, leading to an increased risk of digoxin toxicity.</span></p>",
      "correct_choice_id": 26026,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 73077,
      "choices": [
        {
          "id": 291273,
          "text": "<p><span style=\"font-size:12.0pt;\">Sorbitol accumulation</span></p>"
        },
        {
          "id": 291274,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperglycemia</span></p>"
        },
        {
          "id": 291275,
          "text": "<p><span style=\"font-size:12.0pt;\">Insulin resistance</span></p>"
        },
        {
          "id": 291276,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased insulin secretion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the key mechanism leading to tissue damage in patients with prolonged diabetes? (FMGE JAN 2025)</span></p>",
      "unique_key": "Q6590080",
      "question_audio": null,
      "question_video": null,
      "map_id": 27948837,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:16px;\"><strong>Ans. B) Hyperglycemia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">The <strong>primary mechanism leading to tissue damage</strong> in diabetes is <strong>persistent hyperglycemia</strong>, which:</span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:16px;\"><strong>Leads to oxidative stress</strong></span></li><li><span style=\"font-size:16px;\"><strong>Promotes formation of advanced glycation end-products (AGEs)</strong></span></li><li><span style=\"font-size:16px;\"><strong>Causes endothelial dysfunction and inflammation</strong></span></li></ul><p>&nbsp;</p><p><span style=\"font-size:16px;\">Most <strong>microvascular complications</strong> (<strong>neuropathy, nephropathy, retinopathy</strong>) are <strong>directly attributed to chronic hyperglycemia</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option A. Sorbitol accumulation:</strong> Plays a <strong>secondary role</strong>, particularly in <strong>diabetic neuropathy and cataracts</strong>, but is <strong>not the primary cause of damage</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option C. Insulin resistance:</strong> Contributes to <strong>hyperglycemia</strong>, but does <strong>not directly cause tissue damage</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Option D. Decreased insulin secretion:</strong> Leads to <strong>hyperglycemia</strong>, but tissue damage occurs due to <strong>persistent high glucose levels</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">Hyperglycemia is the fundamental mechanism causing tissue damage in prolonged diabetes, leading to various microvascular complications.</span></p>",
      "correct_choice_id": 291274,
      "solution_audio": null,
      "solution_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73077/FMGE_Jan_2025_Medicine_Q_-_15.mp4",
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "top",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": "https://media.cerebellumacademy.com/media/public/question_media/solution/video/73077/FMGE_Jan_2025_Medicine_Q_-_15.mp4",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54937,
      "choices": [
        {
          "id": 219209,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CK-MB</span></span></span></p>"
        },
        {
          "id": 219210,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lactate dehydrogenase 1 (LDH 1)</span></span></span></p>"
        },
        {
          "id": 219211,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac Troponin I</span></span></span></p>"
        },
        {
          "id": 219212,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemia modified albumin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the earliest marker for myocardial infarction? (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q5286238",
      "question_audio": null,
      "question_video": null,
      "map_id": 27949038,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Ischemia modified albumin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemia-modified albumin (IMA) is considered one of the <strong>earliest markers</strong> for myocardial infarction (MI). It can be detected in the blood within minutes of ischemia and before any significant myocardial necrosis occurs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The novelty of IMA lies in its ability to indicate ischemia even before traditional markers like CK-MB or Troponin I rise, making it particularly useful in the early diagnosis of MI. Its primary utility, however, is in its negative predictive value&mdash;if IMA levels are normal, it&#39;s more likely that the patient is not experiencing an MI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Additionally, </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heart Fatty Acid Binding Protein (H-FABP), one more novel early</span></span></strong><span style=\"font-size:12.0pt\"> marker is noted for its rapid response following myocardial injury. It can be detected early in the blood after the onset of a heart attack, making it a valuable tool for early diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CK-MB:&nbsp;</span></strong><span style=\"font-size:12.0pt\">CK-MB is a marker of myocardial injury that typically rises within <strong>3-4 hours after</strong> the onset of infarction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lactate dehydrogenase 1 (LDH 1):&nbsp;</span></strong><span style=\"font-size:12.0pt\">LDH 1 is a <strong>late marker</strong> of myocardial infarction, typically rising <strong>24-48 hours after the onset</strong>. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Note -</span></strong> <span style=\"font-size:12.0pt\">LDH reacts with<strong> Triphenyl Tetrazole Chloride</strong> <strong>dye</strong>, which is used to visually differentiate between normal and infarcted cardiac tissue during diagnostic procedures. In the presence of this dye, <strong>normal cardiac tissue produces a big red color, while infarcted areas show a yellowish appearance.</strong> This color differentiation helps in identifying and assessing the extent of myocardial damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardiac Troponin I:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Cardiac Troponins, especially Troponin I, are highly specific for myocardial injury and are the gold standard for diagnosing MI. However, they typically rise <strong>within 4-6 hours after the onset</strong>, making them less useful as the earliest marker compared to IMA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemia modified albumin (IMA) is an early biomarker for myocardial infarction, detectable shortly after ischemia begins, and is particularly valuable for its ability to rule out MI when levels are normal.</span></span></span></p>",
      "correct_choice_id": 219212,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}